Molecular testing in thyroid cancer

Matthew T. Olson, Jason D Prescott, Martha A. Zeiger

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cancer of the thyroid gland is associated with genetic aberrations including point mutations in BRAF, RET, and any of the RAS subtypes and chromosomal translocations involving known breakpoints in RET/PTC and PAX8/PPARγ. While the relationships between these molecular abnormalities and tumor carcinogenesis have been well characterized, their relationship to prognosis and usefulness in clinical care is less clear. In this chapter, we discuss the molecular aberrations, how they are detected, how they correlate with cytomorphological and histomorphological findings, and how useful the constellation of this information may be in current patient management. We also compare and contrast the currently available molecular testing strategies-the gene expression classifier and the somatic mutation panel-for stratifying risk in cytomorphologically indeterminate nodules biopsied by fine needle aspiration.

Original languageEnglish (US)
Title of host publicationMolecular Testing in Cancer
PublisherSpringer New York
Pages319-329
Number of pages11
Volume9781489980502
ISBN (Print)9781489980502, 1489980490, 9781489980496
DOIs
StatePublished - Oct 1 2014

Fingerprint

Genetic Translocation
Peroxisome Proliferator-Activated Receptors
Factor IX
Fine Needle Biopsy
Thyroid Neoplasms
Point Mutation
Thyroid Gland
Carcinogenesis
Gene Expression
Mutation
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Olson, M. T., Prescott, J. D., & Zeiger, M. A. (2014). Molecular testing in thyroid cancer. In Molecular Testing in Cancer (Vol. 9781489980502, pp. 319-329). Springer New York. https://doi.org/10.1007/978-1-4899-8050-2_19

Molecular testing in thyroid cancer. / Olson, Matthew T.; Prescott, Jason D; Zeiger, Martha A.

Molecular Testing in Cancer. Vol. 9781489980502 Springer New York, 2014. p. 319-329.

Research output: Chapter in Book/Report/Conference proceedingChapter

Olson, MT, Prescott, JD & Zeiger, MA 2014, Molecular testing in thyroid cancer. in Molecular Testing in Cancer. vol. 9781489980502, Springer New York, pp. 319-329. https://doi.org/10.1007/978-1-4899-8050-2_19
Olson MT, Prescott JD, Zeiger MA. Molecular testing in thyroid cancer. In Molecular Testing in Cancer. Vol. 9781489980502. Springer New York. 2014. p. 319-329 https://doi.org/10.1007/978-1-4899-8050-2_19
Olson, Matthew T. ; Prescott, Jason D ; Zeiger, Martha A. / Molecular testing in thyroid cancer. Molecular Testing in Cancer. Vol. 9781489980502 Springer New York, 2014. pp. 319-329
@inbook{6705004a8a014e8d92bf3a38c777f9cd,
title = "Molecular testing in thyroid cancer",
abstract = "Cancer of the thyroid gland is associated with genetic aberrations including point mutations in BRAF, RET, and any of the RAS subtypes and chromosomal translocations involving known breakpoints in RET/PTC and PAX8/PPARγ. While the relationships between these molecular abnormalities and tumor carcinogenesis have been well characterized, their relationship to prognosis and usefulness in clinical care is less clear. In this chapter, we discuss the molecular aberrations, how they are detected, how they correlate with cytomorphological and histomorphological findings, and how useful the constellation of this information may be in current patient management. We also compare and contrast the currently available molecular testing strategies-the gene expression classifier and the somatic mutation panel-for stratifying risk in cytomorphologically indeterminate nodules biopsied by fine needle aspiration.",
author = "Olson, {Matthew T.} and Prescott, {Jason D} and Zeiger, {Martha A.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1007/978-1-4899-8050-2_19",
language = "English (US)",
isbn = "9781489980502",
volume = "9781489980502",
pages = "319--329",
booktitle = "Molecular Testing in Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Molecular testing in thyroid cancer

AU - Olson, Matthew T.

AU - Prescott, Jason D

AU - Zeiger, Martha A.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Cancer of the thyroid gland is associated with genetic aberrations including point mutations in BRAF, RET, and any of the RAS subtypes and chromosomal translocations involving known breakpoints in RET/PTC and PAX8/PPARγ. While the relationships between these molecular abnormalities and tumor carcinogenesis have been well characterized, their relationship to prognosis and usefulness in clinical care is less clear. In this chapter, we discuss the molecular aberrations, how they are detected, how they correlate with cytomorphological and histomorphological findings, and how useful the constellation of this information may be in current patient management. We also compare and contrast the currently available molecular testing strategies-the gene expression classifier and the somatic mutation panel-for stratifying risk in cytomorphologically indeterminate nodules biopsied by fine needle aspiration.

AB - Cancer of the thyroid gland is associated with genetic aberrations including point mutations in BRAF, RET, and any of the RAS subtypes and chromosomal translocations involving known breakpoints in RET/PTC and PAX8/PPARγ. While the relationships between these molecular abnormalities and tumor carcinogenesis have been well characterized, their relationship to prognosis and usefulness in clinical care is less clear. In this chapter, we discuss the molecular aberrations, how they are detected, how they correlate with cytomorphological and histomorphological findings, and how useful the constellation of this information may be in current patient management. We also compare and contrast the currently available molecular testing strategies-the gene expression classifier and the somatic mutation panel-for stratifying risk in cytomorphologically indeterminate nodules biopsied by fine needle aspiration.

UR - http://www.scopus.com/inward/record.url?scp=84930063218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930063218&partnerID=8YFLogxK

U2 - 10.1007/978-1-4899-8050-2_19

DO - 10.1007/978-1-4899-8050-2_19

M3 - Chapter

SN - 9781489980502

SN - 1489980490

SN - 9781489980496

VL - 9781489980502

SP - 319

EP - 329

BT - Molecular Testing in Cancer

PB - Springer New York

ER -